Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
First and only PARP inhibitor to improve overall survival in early breast cancer
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Subscribe To Our Newsletter & Stay Updated
